4635-08-9

Usage

Uses

Used in Chemical Research:
5-Bromo-2,3-diaminopyridine, 97 is used as a research compound for its ability to facilitate numerous chemical reactions. Its unique structure allows for the exploration of new chemical pathways and the synthesis of novel compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-Bromo-2,3-diaminopyridine, 97 is used as a key intermediate in the synthesis of various pharmaceutical products. Its presence in the molecular structure can influence the properties and effectiveness of the final drug, making it a valuable component in drug development.
Used in Organic Synthesis:
5-Bromo-2,3-diaminopyridine, 97 is employed as a building block in organic synthesis, where it contributes to the formation of complex organic molecules. Its versatility in reacting with other compounds makes it a useful component in the creation of a wide range of organic compounds.
Used in Material Science:
In material science, 5-Bromo-2,3-diaminopyridine, 97 may be used to develop new materials with specific properties. Its incorporation into the molecular structure of materials can lead to the creation of materials with unique characteristics, such as improved stability or enhanced reactivity.
Used in Analytical Chemistry:
5-Bromo-2,3-diaminopyridine, 97 can be used as a reagent or a reference compound in analytical chemistry. Its distinct chemical properties make it suitable for use in various analytical techniques, such as spectroscopy or chromatography, to identify and quantify other compounds.

InChI:InChI=1/C5H6BrN3/c6-3-1-9-2-4(7)5(3)8/h1-2H,7H2,(H2,8,9)

Upstream product

• 504-24-5 4-aminopyridine 
• 26482-55-3 4-(nitroamino)pyridine 
• 1681-37-4 4-amino-3-nitropyridine 
• 89284-05-9 4-amino-3-bromo-5-nitropyridine 

Downstream Products

• 161836-12-0 7-bromo-1,3-dihydro-2H-imidazo<4,5-c>pyridin-2-one 
• 1305317-09-2 N-(2,3-diphenylpyrido[3,4-b]pyrazin-8-yl)benzophenone imine 
• 1305317-10-5 N-[2,3-bis(4-methoxyphenyl)pyrido[3,4-b]pyrazin-8-yl]benzophenone imine 
• 788821-74-9 8-amino-2,3-diphenylpyrido[3,4-b]pyrazine 
• 1305317-11-6 8-amino-2,3-bis(4-methoxyphenyl)pyrido[3,4-b]pyrazine 
• 1305317-14-9 N-(3-bromophenyl)-2,3-diphenylpyrido[3,4-b]pyrazin-8-amine 
• 1305317-15-0 N-(3-chloro-4-fluorophenyl)-2,3-diphenylpyrido[3,4-b]pyrazin-8-amine 
• 1305317-16-1 N-(2,3-diphenylpyrido[3,4-b]pyrazin-8-yl)-N'-ethylurea 
• 1305317-17-2 N-(2,3-diphenylpyrido[3,4-b]pyrazin-8-yl)-N'-phenylurea 
• 1305317-18-3 N-(2,3-diphenylpyrido[3,4-b]pyrazin-8-yl)-N'-(3-methoxyphenyl)urea 
• 1305317-19-4 N-(3-chlorophenyl)-N'-(2,3-diphenylpyrido[3,4-b]pyrazin-8-yl)urea 
• 1305317-20-7 N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(2,3-diphenylpyrido[3,4-b]pyrazin-8-yl)urea 
• 1305317-22-9 N-[2,3-bis(4-methoxyphenyl)pyrido[3,4-b]pyrazin-8-yl]-N'-phenylurea 
• 1305317-24-1 N-(2,3-diphenylpyrido[3,4-b]pyrazin-8-yl)-N'-ethylthiourea 

Relevant academic research and scientific papers

Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and in Vivo Efficacy in the Plasmodium falciparum NSG Mouse Model

A series of 2,4-disubstituted imidazopyridines, originating from a SoftFocus Kinase library, was identified from a high throughput phenotypic screen against the human malaria parasite Plasmodium falciparum. Hit compounds showed moderate asexual blood stage activity. During lead optimization, several issues were flagged such as cross-resistance against the multidrug-resistant K1 strain, in vitro cytotoxicity, and cardiotoxicity and were addressed through structure-Activity and structure-property relationship studies. Pharmacokinetic properties were assessed in mice for compounds showing desirable in vitro activity, a selectivity window over cytotoxicity, and microsomal metabolic stability. Frontrunner compound 37 showed good exposure in mice combined with good in vitro activity against the malaria parasite, which translated into in vivo efficacy in the P. falciparum NOD-scid IL-2Rnull (NSG) mouse model. Preliminary mechanistic studies suggest inhibition of hemozoin formation as a contributing mode of action.

Preparation of novel 2,3,8-trisubstituted pyrido[3,4-b]pyrazines and pyrido[2,3-b]pyrazines

A four-step synthesis of 8-bromo-2,3-disubstituted pyrido[3,4-b]pyrazines and a six-step synthesis of 8-amino-2,3-disubstituted pyrido[3,4-b]pyrazines have been developed. A particularly valuable feature of this synthetic route is the possibility to build

Diaminopyridine compounds and methods of use

The present invention relates to compositions and method for inhibiting nonenzymatic cross-linking (protein aging) which contain diaminopyridines and derivates thereof. Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.